Preventing contrast induced nephropathy and managing patients with chronic kidney disease remain major challenges in the ...
Dec. 19, 2024 โ Drinking multiple cups of coffee a day may help prevent cognitive decline in people with atrial ...
Pfizer has awarded $80,000 to Rutgers Robert Wood Johnson Medical School (RWJMS) to fund an Amyloidosis Fellowship at ...
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
Dec. 11, 2024 โ Older adults whose blood pressure fluctuates over time may be more likely to have problems with thinking ...
Dec. 11, 2024 โ Genetesis, Inc. has launched the CardioFlux Membership program. CardioFlux Membership is designed to be ...
Dec. 12, 2024 โ Physicians have a new treatment option for many of the sickest pediatric patients with heart failure and ...
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
Dec. 13, 2024 โ Sensome has announced positive results from two studies of its Clotild Smart Guidewire System ...
Bally Ribbon Mills (BRM) offers a broad product line of medical textiles and fabrics ideal for use in cardiovascular ...
Dec. 4, 2024 โ Cleerly has successfully closed its latest Series C extension funding round, raising a total of $106 ...
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
Nov. 18, 2024 โ In November, Esperion presented an analysis from the CLEAR Outcomes study focused on patients with ...
Nov. 22, 2024 โ BridgeBio Pharma, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved ...
Nov. 21, 2024 โ Royal Philips plans to unveil its next-generation 1.5T BlueSeal MR wide-bore scanner at RSNA 2024 in ...
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
Nov. 18, 2024 โ Abbott recently announced new data for the Amplatzer Amulet Left Atrial Appendage (LAA) Occluder to ...
Nov. 18, 2024 โ Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...
Nov. 16, 2024 Anthos Therapeutics, Inc.recently presented new data at the American Heart Association (AHA) Scientific ...